{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:07:54Z","timestamp":1786374474627,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Improved survival among patients with neuroendocrine tumors (NETs), has increased attention to long-term oncologic outcomes, including second primary tumors (SPTs). However, their clinical patterns and timing remain incompletely characterized. In this retrospective single-center cohort study, we analyzed 201 patients with NETs diagnosed between 2005 and 2023. SPTs were defined according to Warren\u2013Gates criteria and classified as synchronous (\u22646 months) or metachronous (&gt;6 months). Standardized incidence ratios were calculated using national cancer registry data. Predictors of SPT occurrence were explored using regression and competing-risk models. Thirty-five patients (17.4%) developed an additional malignancy. Patients with SPTs were older at NET diagnosis (median: 65 vs. 58 years;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.006), while most other clinicopathological characteristics were similar. The most frequent SPTs were colorectal (26%), genitourinary (20%), and breast cancers (11%). SPTs were synchronous (71%), whereas metachronous tumors occurred at a median of 4.9 years after NET diagnosis. Standardized incidence ratios suggested an increased occurrence of colorectal, melanoma, and breast cancers, but estimates were imprecise because of limited event numbers. Older age at NET diagnosis independently predicted SPT occurrence (odds ratio: 1.62 per SD; 95% confidence interval: 1.07\u20132.54;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.021), while no other variable reached statistical significance. Competing-risk analysis demonstrated metachronous SPTs of approximately 5\u20136% at 5 years and 7.5% at 10 years. Approximately one in six patients developed an additional malignancy, most frequently detected synchronously. Diagnostic intensity during initial staging may contribute to SPT detection, while long-term risk of metachronous tumors persists. These results support individualized follow-up with attention to gastrointestinal and site-specific cancer surveillance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cej.0000000000001035","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:00:10Z","timestamp":1786370410000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Second primary malignancies in neuroendocrine tumors: a single-center cohort study"],"prefix":"10.1097","author":[{"given":"Borislav","family":"Belev","sequence":"first","affiliation":[{"name":"Department of Oncology, Division of Medical Oncology, Clinical Hospital Centre Zagreb"},{"name":"University of Zagreb School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Racetin","sequence":"additional","affiliation":[{"name":"Region Sk\u00e5ne, Lasarettet i Ystad, Ystad, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Seitz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Haematology and Oncology, County Hospital Karlovac, Karlovac"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Vorkapic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Haematology and Oncology, County Hospital Slavonski Brod, Slavonski Brod"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bilic","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Medical Oncology, Clinical Hospital Centre Zagreb"},{"name":"University of Zagreb School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niksa","family":"Librenjak","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Medical Oncology, Clinical Hospital Centre Zagreb"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Likic","sequence":"additional","affiliation":[{"name":"University of Zagreb School of Medicine, Zagreb, Croatia"},{"name":"Department of Internal Medicine, Division of Clinical Pharmacology and Therapeutics, Clinical Hospital Centre Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/jamaoncol.2021.4531","article-title":"Incidence and predictors of second primary cancers in patients with neuroendocrine tumors.","volume":"7","author":"Bateni","year":"2021","journal-title":"JAMA Oncol"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381716","article-title":"Incidence of second primary malignancies in patients with neuroendocrine tumours.","volume":"102","author":"Clift","year":"2015","journal-title":"Neuroendocrinology"},{"key":"R6-20260810","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ijc.1317","article-title":"Second primary neoplasms in 633,964 cancer patients in Sweden, 1958\u20131996.","volume":"93","author":"Dong","year":"2001","journal-title":"Int J Cancer"},{"key":"R8-20260810","first-page":"397","article-title":"Second primary malignancies in patients with a gastrointestinal neuroendocrine tumour: a case report and review of the literature.","volume":"73","author":"Ferrante","year":"2010","journal-title":"Acta Gastroenterol Belg"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"R10-20260810","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression.","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat Med"},{"key":"R12-20260810","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1530\/ERC-11-0315","article-title":"Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas.","volume":"19","author":"Kamp","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"R13-20260810","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"R14-20260810","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1159\/000530238","article-title":"Second primary malignancies in patients with a neuroendocrine neoplasm in England.","volume":"113","author":"Russell","year":"2023","journal-title":"Neuroendocrinology"},{"key":"R15-20260810","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours.","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"R16-20260810","first-page":"1358","article-title":"Multiple primary malignant tumors: a survey of the literature and a statistical study.","volume":"16","author":"Warren","year":"1932","journal-title":"Am J Cancer"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse.","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw"},{"key":"R19-20260810","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CEJ.0000000000001035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:00:12Z","timestamp":1786370412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CEJ.0000000000001035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000001035","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"2026-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}